$AKTX AKTX has the magic-- if it comes out that LTB4 has a significant role in certain indications it will be huge. Quote, "The roles that LTB4 plays in the amplification of immune responses are still emerging, but LTB4 activity has been implicated in diseases as diverse as asthma and COPD, blistering skin disease, pulmonary arterial hypertension, thrombosis, diabetes and metastatic cancer.” Because of this, I think Alexion will partner with AKTX on TMA trial and who knows may do buy offer. A quote from a study I found, "As expected, eculizumab did not have any neutralizing effect on LTB4." Oh, and one of the side effects of Soliris is a type of thrombosis. drugs.com/disease-interacti...
  • 9
  • 4